1951-38-8

Usage

Uses

Used in Chemical Synthesis:
2-Methoxyisophthalic Acid is used as a key intermediate in the synthesis of various chemicals for different applications. Its unique structure allows it to be a versatile building block in the creation of new compounds with specific properties.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Methoxyisophthalic Acid is used as a starting material for the development of new drugs. Its chemical properties make it suitable for the synthesis of pharmaceutical compounds with potential therapeutic effects.
Used in Polymer Industry:
2-Methoxyisophthalic Acid is used as a monomer in the production of polymers. Its ability to form covalent bonds with other monomers contributes to the development of polymers with specific characteristics, such as improved strength, flexibility, or chemical resistance.
Used in Laboratory Research:
2-Methoxyisophthalic Acid is used as a research chemical in laboratories for studying its properties and potential applications. Researchers can explore its reactivity, stability, and interactions with other chemicals to gain insights into its potential uses and limitations.
Used in Environmental Regulations:
Due to its corrosive nature, 2-Methoxyisophthalic Acid is subject to environmental regulations for its disposal. These regulations ensure that the chemical is handled and disposed of safely to minimize its impact on the environment and human health.

InChI:InChI=1/C9H8O5/c1-14-7-3-5(8(10)11)2-6(4-7)9(12)13/h2-4H,1H3,(H,10,11)(H,12,13)

Upstream product

• 1004-66-6 2-methoxy-1,3-dimethylbenzene 
• 26507-91-5 2-methoxy-3-methylbenzoic acid 
• 606-19-9 2-hydroxyisophthalic acid 
• 77-78-1 dimethyl sulfate 
• 124-38-9 carbon dioxide 
• 38474-03-2 1-(isopropylthio)-3-methoxybenzene 
• 36727-13-6 2-methoxy-1,3-benzenedicarboxylic acid dimethyl ester 
• 576-22-7 2-Bromo-m-xylene 
• 14804-38-7 5-bromo-2-methoxy-1,3-dimethylbenzene 
• 83-40-9 3-methylsalicylic acid 
• 58425-33-5 potassium 2,6-dimethylphenolate 
• 576-26-1 2.6-dimethylphenol 
• 141778-90-7 2,2′-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid 
• 67639-61-6 2-methoxy-3-methylanisaldehyde 

Downstream Products

• 935510-50-2 C₅₃H₈₄N₄O₇ 
• 1031691-48-1 C₁₁₃H₁₉₀N₁₄O₁₉ 
• 1417905-73-7 C₁₉H₁₈FNO₆ 
• 1417905-68-0 C₃₄H₂₈N₂O₃ 
• 1417905-59-9 C₂₁H₁₇NO₄ 
• 1417905-49-7 C₁₆H₁₄FNO₄ 
• 1417905-57-7 C₁₅H₁₂FNO₄ 
• 1139945-03-1 C₁₅H₁₂FNO₄ 
• 1417905-48-6 C₁₆H₁₄FNO₄ 
• 1417905-65-7 C₂₂H₁₆Cl₄N₂O₃ 
• 1417905-56-6 C₁₅H₁₁Cl₂NO₄ 
• 1417905-47-5 C₁₆H₁₃Cl₂NO₄ 
• 1417905-64-6 C₂₃H₁₈Cl₄N₂O₃ 
• 1417905-67-9 C₂₂H₁₈Cl₂N₂O₃ 

Relevant academic research and scientific papers

Ultrabright Lanthanide Nanoparticles

Tb-doped La0.9Tb0.1F3 nanoparticles were prepared by a simple and reproducible microwave-assisted synthetic protocol in water. The nanoparticles were characterized by XRD, TEM, dynamic light scattering and inductively coup

Complexes and Ligands

The present application provides ligands and fluorescent or luminescent complexes comprising these ligands.

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

Ultrabright Terbium Nanoparticles for FRET Biosensing and in Situ Imaging of Epidermal Growth Factor Receptors**

Lanthanide-doped nanoparticles (LnNPs) have become an important class of fluorophores for advanced biosensing and bioimaging. LnNPs that are photosensitized by surface-attached antenna ligands can possess exceptional brightness. However, their functional

A series of 3D metal organic frameworks based on [24-MC-6] metallacrown clusters: Structure, magnetic and luminescence properties

Four isostructural metal organic frameworks (MOFs), namely [Co 6(HipO)6]·6H2O (1), [Mn 6(HipO)6]·6H2O (2), [Cd 6(HipO)6]·6H2O (3) and [Zn 6(HipO)6]·7H2O (4) (H3ipO = 2-hydroxyisophthalic acid), were synthesized and structurally characterized. They have a 3D (4,6)-connected framework based on [24-MC-6] metallacrown clusters ([24-MC-6]-based MOFs). The arrangements of the 24-MC-6 metallacrown SBUs show a regular change indicated by the orientation of their symmetry axes, resulting in a special dense packing mode different from other [24-MC-6]-based MOFs. The analysis of SQUID measurements reveal that compound 1 displays the dominant antiferromagnetic exchanges in 300-10 K between the adjacent Co(ii) ions and a ferromagnetic-like behavior at lower temperatures, whereas compound 2 shows an antiferromagnetic interaction between the adjacent Mn(ii) ions. Compound 1 exhibits a magnetocaloric effect (MCE) with the resulting entropy change (-ΔSm) of 15.20 J kg-1 K-1 for ΔH = 50 kG at 6 K, which is the highest value among the cobalt-based MOFs with MCE reported so far. The luminescence properties of compounds 3 and 4 were studied, both of them exhibit photoluminescence in the solid state at room temperature which can be ascribed to intraligand π→π* transitions. This journal is the Partner Organisations 2014.

Light-induced water oxidation by a Ru complex containing a bio-inspired ligand

The new Ru complex 8 containing the bio-inspired ligand 7 was successfully synthesized and characterized. Complex 8 efficiently catalyzes water oxidation using CeIV and RuIII as chemical oxidants. More importantly, this complex has a sufficiently low overpotential to utilize ruthenium polypyridyl-type complexes as photosensitizers. Water splitting: A bio-inspired ligand containing imidazole and phenol functionalities has been synthesized. The corresponding Ru complex (1) could efficiently catalyze water oxidation under visible light illumination using Ru polypyridyl-type complexes as photosensitizers. Copyright

LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES

The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.

A new class of intramolecularly hydrogen-bonded dendrons based on a 2-methoxyisophthalamide repeat unit

(Chemical Equation Presented). The synthesis and conformational properties of folded dendrons based on a 2-methoxyisophthalamide (2-OMe-IPA) repeat unit are described. The hydrodynamic properties of dendrons preorganized via the syn-syn conformational pre

A minimalist approach to C-H activation by copper

The complex [Cu2(1)2]2+ (1=1,3-bis(1-methyl-1H-benzimidazol-2-yl)benzene) undergoes slow oxidation by dioxygen in DMF solution to give the hydroxylated product [Cu 2(2-H)2]2+ (2=2,6-bis(1-methyl-1H-benzimidazol- 2-yl)phenol) characterized by an X-ray crystal-structure analysis. The oxidation occurs much faster when CuII is mixed with 1 in the presence of H2O2, with 80% hydroxylation observed within a few minutes. The mononuclear complex formed with 1-methyl-2-phenyl-1H-benzimidazole (3) shows no hydroxylation under these conditions. It is concluded that the hydroxylation requires the presence of a ligand capable of stabilizing a binuclear species, but no special coordinative activation of the copper is required.

(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.